Scarica l'app Stockscreener
10.25
3.21%
-0.34
Precedente Chiudi:
$10.59
Aprire:
$10.92
Volume 24 ore:
91,767
Relative Volume:
1.95
Capitalizzazione di mercato:
$80.65M
Reddito:
-
Utile/perdita netta:
$-31.48M
Rapporto P/E:
-9.8558
EPS:
-1.04
Flusso di cassa netto:
$-28.71M
1 W Prestazione:
-17.64%
1M Prestazione:
+20.73%
6M Prestazione:
-52.33%
1 anno Prestazione:
-14.58%
Intervallo 1D:
$10.22
$11.20
Intervallo di 1 settimana:
$10.25
$19.63
Portata 52W:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Nome
Forte Biosciences Inc
Settore
Industria
Telefono
(310) 618-6994
Indirizzo
3060 PEGASUS PARK DRIVE, DALLAS, CA
Confronta FBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
10.25 | 80.65M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.31 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.21 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.85 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
561.10 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
261.73 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-21 | Iniziato | TD Cowen | Buy |
| 2024-04-08 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | Aggiornamento | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | Downgrade | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | Downgrade | Truist | Buy → Hold |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-03-26 | Iniziato | Citigroup | Buy |
| 2020-08-28 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | Iniziato | Truist | Buy |
Mostra tutto
Forte Biosciences Inc Borsa (FBRX) Ultime notizie
Valkyrie Balance Sheet Opportunities ETF (NYSEARCA:VBB) Trading 0.4% Higher – Here’s Why - Defense World
Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
With Forte Biosciences Up 28%, Insider Buyers Count Their Returns - simplywall.st
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Forte Biosciences (FBRX) Receives Buy Rating as FB-102 Shows Blockbuster Potential | FBRX Stock News - GuruFocus
Forte Biosciences reports annual meeting results By Investing.com - Investing.com Nigeria
Forte Biosciences reports annual meeting results - Investing.com
Forte Biosciences Elects New Directors at Annual Meeting - TipRanks
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Top Premarket Decliners - marketscreener.com
Forte Biosciences Reports Increased Losses Amid R&D Expansion - TipRanks
Forte Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Forte Biosciences Q1 Operating Expenses USD 16.124 Million - marketscreener.com
Forte Biosciences (FBRX) Advances Trials for FB102 in Celiac Disease and Vitiligo | FBRX Stock News - GuruFocus
Forte Biosciences reports Q1 EPS ($1.37), consensus (95c) - TipRanks
Forte Biosciences, Inc. Announces Results and Provides Update - Eagle-Tribune
Forte Biosciences Q1: Celiac Disease Trial Results Imminent, New Vitiligo Study Launches - Stock Titan
Stock Traders Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Forte Biosciences (FBRX) Expected to Announce Earnings on Monday - Defense World
JPMorgan Chase & Co. Trims Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Royal Bank of Canada Has Lowered Expectations for Zimmer Biomet (NYSE:ZBH) Stock Price - Defense World
JPMorgan Chase & Co. Buys New Holdings in Innovator U.S. Equity Accelerated ETF – January (BATS:XDJA) - Defense World
(FBRX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Stock Position in AmpliTech Group, Inc. (NASDAQ:AMPG) - Defense World
Geode Capital Management LLC Increases Position in Forte Biosciences, Inc. (NASDAQ:FBRX) - Defense World
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Meta Doubles Down on AI: Is the Stock Ready to Skyrocket? - The Globe and Mail
Shining a Light on IL-13: Optimizing Moderate-to-Severe Atopic Dermatitis Treatment in Daily Practice - Healio
Forte Biosciences sets Annual Meeting for May 29 By Investing.com - Investing.com Canada
Forte Biosciences sets Annual Meeting for May 29 - Investing.com Australia
Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
Mr. Ethan Billings recommends paying close attention to biotech stocks - FinancialContent
Profit from Trump’s Tariff Playbook with TipRanks’ New Comparison Tool - The Globe and Mail
Nvidia and Broadcom Helped Propel This ETF 18% Higher in a Single Day. Here's Why It's Still a Buy Now. - The Globe and Mail
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Analysts Issue Forecasts for FBRX Q2 Earnings - Defense World
Equities Analysts Offer Predictions for FBRX FY2025 Earnings - Defense World
(FBRX) Investment Analysis - news.stocktradersdaily.com
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy - MSN
Forte Biosciences (NASDAQ:FBRX) Given New $61.00 Price Target at Chardan Capital - The AM Reporter
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Chardan Capital Issues Pessimistic Forecast for Forte Biosciences (NASDAQ:FBRX) Stock Price - Defense World
Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating - MarketScreener
Forte Biosciences Reports 2024 Progress and Financials - TipRanks
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Yahoo
Forte's Celiac Treatment Shows Promise: Zero Dropouts and $58.4M War Chest - Stock Titan
Forte Biosciences Inc Azioni (FBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Forte Biosciences Inc Azioni (FBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,151 |
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
203,849 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,910,424 |
0.78%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):